Related Experiment Video
Updated: Apr 28, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Biotransformation of resibufogenin by Actinomucor elegans
Li-Yan Mou1, Xiu-Lan Xin, Liang Chen
1a School of Traditional Chinese Medicines, Shenyang Pharmaceutical University , Shenyang 110016 , China.
Abstract:
Resibufogenin (RB), a major bioactive bufadienolide, has the potential anticancer activity. In the present work, biotransformation of RB by Actinomucor elegans AS 3.2778 yielded five products, namely 3-oxo-resibufogenin (1), 3-epi-resibufogenin (2), 3-epi-12-oxo-hydroxylresibufogenin (3), 3α-acetoxy-15α-hydroxylbufalin (4), and 3-epi-12α-hydroxylresibufogenin (5), respectively. Among them, metabolites 3 and 4 are previously unreported. The chemical structures of metabolites 1-5 were fully elucidated on the basis of 2D NMR and HR-MS. The highly stereo- and regio-specific isomerization, hydroxylation, and esterification reactions were observed in the biotransformation process of RB by A. elegans. Their cytotoxicities against A549 and H1299 cells were evaluated.
Related Concept Videos
Drug Biotransformation: Overview
Microbial Bioremediation of Uranium

